Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

RADX stock hub

Radiopharm Theranostics Limited has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

RADXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

48.8M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

RADX

In the news

Latest news · RADX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-92.1

P25 -105.6P50 -46.5P75 -3.1

ROIC-51

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All RADX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

174

Groups with data

Currency

AUD

Showing 174 of 174 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001949257
Company name	Radiopharm Theranostics Limited
Country	Australia
Country code	US
Employees	14
Enterprise value	$22.4M
Exchange	NASDAQ
Financial currency	AUD
First seen	2026-05-09
Industry	Biotechnology
Isin	US75041J1016
Last refreshed	2026-05-10
Market cap	$48.8M
Market cap category	Nano-Cap
Price	$4
Price currency	USD
Rev Per Employee	775,576.86x
Sector	Healthcare
Sic	2834
Symbol	RADX
Website	https://www.radiopharmtheranostics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-63.72%
EV/Sales	2.07x
FCF yield	-55.17%
P/B ratio	1.46x
P/S ratio	4.49x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-255.63%
EBITDA Margin	-240.69%
Gross margin	-136.51%
Gross Profit	$-14.8M
Net Income	$-31.1M
Net Income Growth Years	1%
Pretax Margin	-287.54%
Profit Margin	-286.16%
Profit Per Employee	$-2.2M
ROA	-28.33
ROCE	-54.84
ROE	-92.1
ROIC	-51.02

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-7.84%
EPS Growth Years	1
Revenue Growth	4,823.49x
Revenue Growth Q	154.52x
Revenue Growth Years	2x
Revenue Growth3 Y	56.32x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.18
Assets	$60.8M
Cash	$23M
Current Assets	$33.4M
Current Liabilities	$11.1M
Equity	$33.3M
Interest Coverage	-319.1
Liabilities	$27.5M
Long Term Assets	$27.4M
Long Term Liabilities	$16.4M
Net Cash	$23M
Net Cash By Market Cap	$47.21
Net Cash Growth	1,722.43%
Net Debt Equity	$-0.69
Tangible Book Value	$4.5M
Tangible Book Value Per Share	$0
WACC	8.55

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.01
Net Working Capital	$-2.5M
Quick ratio	3
Working Capital	$20.5M
Working Capital Turnover	$0.89

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-114.63%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-7.83%
200-day SMA	5.12
50-day SMA	4.58
50-day SMA vs 200-day SMA	50under200
All Time High	50.82
All Time High Change	-92.13%
All Time High Date	2024-12-06
All Time Low	3.5
All Time Low Change	14.42%
All Time Low Date	2025-04-07
ATR	0.25
Beta	0.78
Ch YTD	-23.37
High	4.19
High52	16.25
High52 Date	2025-12-15
High52ch	-75.38%
Low	3.96
Low52	3.62
Low52 Date	2025-12-10
Low52ch	10.5%
Ma50ch	-12.64%
Price vs 200-day SMA	-21.92%
RSI	35.25
RSI Monthly	43.97
RSI Weekly	35.29
Sharpe ratio	0.56x
Sortino ratio	1.5
Total Return	-114.63%
Tr YTD	-23.37
Tr1m	-8.05%
Tr1w	-9.3%
Tr3m	-19.52%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Ratings	Strong Buy
Operating Income	$-27.8M
Operating margin	-255.6
Price target	$17
Price Target Change	$325

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2,370,985,654%
Float Percent	66.9%
Shares Insiders	7.21%
Shares Institutions	10.45%
Shares Out	3,544,216,160
Shares Qo Q	10.4%
Shares Yo Y	114.63%
Short Float	0%
Short Ratio	0.11
Short Shares	0

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-28.2M
Average Volume	31,062.05x
Bv Per Share	0.01
Ch1m	-8.05
Ch1w	-9.3
Ch1y	-7.83
Ch3m	-19.52
Ch6m	-19.94
Change	-3.61%
Change From Open	-1.48
Close	4.15
Days Gap	-2.17
Depreciation Amortization	1,764,112.6
Dollar Volume	322,644
Earnings Date	2026-05-28
EBIT	$-27.8M
EBITDA	$-26.1M
EPS	$-0.01
F Score	3
FCF	$-26.9M
FCF EV Yield	-119.91x
FCF Per Share	$-0.01
Financing CF	26,243,535
Fiscal Year End	June
Founded	2,021
Income Tax	$91,133
Investing CF	-2,416,128
Is Primary Listing	0
Is Spac	No
Last Earnings Date	2026-02-26
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2025-09-18
Ma150	5
Ma150ch	-19.94%
Ma20	4.48
Ma20ch	-10.75%
Net CF	-1,281,711
Next Earnings Date	2026-05-28
Open	4.06
Optionable	No
Position In Range	17.78
Post Close	4
Postmarket Change Percent	0.75
Postmarket Price	$4.03
Ppne	36,089
Price Date	2026-05-08
Ptbv Ratio	10.91
Relative Volume	2.61x
Revenue	10,858,076x
SBC By Revenue	11.64x
Share Based Comp	1,264,240
Tax By Revenue	0.84x
Tr6m	-19.93%
Volume	80,661
Z Score	-2.66

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does RADX pay a dividend?

Capital-return profile for this ticker.

Performance

RADX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns RADX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+10.5%

Float: +66.9% of shares outstanding

Insider ownership

+7.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

RADX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

35.3

Neutral momentum band

Price vs 200-day MA

-21.9%

50/200-day relationship not available

Beta (5Y)

0.78

Less volatile than the market

Sharpe ratio

0.56

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About RADX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current RADX stock rating?

Radiopharm Theranostics Limited is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full RADX analysis?

The full report lives at /stocks/RADX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for RADX?

The latest report frames RADX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the RADX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.